Drug intelligence / Profile preview

DR507

Development stage: Unknown
Lead developer: Doer Bio

Overview

DR507: sourced facts only. name: "Leveraging these advantages, three prodrugs (DR510 targeting hEGFR, DR507 targeting hTROP-2, and DR508 targeting hEpCAM) have been characterized." [DOI:10.1158/1535-7163.TARG-25-C010]; target: "Leveraging these advantages, three prodrugs (DR510 targeting hEGFR, DR507 targeting hTROP-2, and DR508 targeting hEpCAM) have been characterized." [DOI:10.1158/1535-7163.TARG-25-C010]; developer: "Zhejiang Doer Biologics Co., Ltd., HANGZHOU, China." [DOI:10.1158/1535-7163.TARG-25-C010]

Targets

TACSTD2 (Tumor-associated calcium signal transducer 2)

Beyond the preview

Go deeper on DR507.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DR507.